Wed, Jul 23, 2014, 4:45 AM EDT - U.S. Markets open in 4 hrs 45 mins

Recent

% | $
Click the to save as a favorite.

UnitedHealth Group Incorporated Message Board

sam_0534 171 posts  |  Last Activity: 13 hours ago Member since: Feb 8, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • and Paulson 11.5 %..looks good to me

    Sentiment: Strong Buy

  • News Breaks
    May 12, 2014
    07:17 EDT QCOR, MNK Questcor downgraded to Neutral from Overweight at Piper Jaffray
    Piper Jaffray downgraded Questcor (QCOR) to Neutral saying the investigations into the company are unlikely to derail the takeover by Mallinckrodt (MNK). Piper lowered its price target for shares to $96 from $98.

    Sentiment: Strong Buy

  • sam_0534 by sam_0534 Apr 30, 2014 9:04 AM Flag

    ActiveTraderPro.com BannerPrint Print
    A A A
    All Content and Data provided by Third-Parties — Terms of Use
    Mallinckrodt Pharmaceuticals to Present New Clinical Data at American Pain Society Annual Scientific MeetingXARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) and PENNSAID® 2% (diclofenac sodium topical solution 2% w/w) Studies Offer Additional Product Information
    BUSINESS WIRE 6:00 AM ET 4/30/2014
    Symbol Last Price Change
    MNK 68.6down 0 (0%)
    QUOTES AS OF 04:04:06 PM ET 04/29/2014
    TAMPA, Fla.--(BUSINESS WIRE)-- Mallinckrodt(MNK) will present new data for two of its recently approved pain medications – XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) and PENNSAID® 2% (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) – during the 33rd Annual Scientific Meeting of the American Pain Society (APS) to be held April 30 - May 3, 2014 in Tampa, Florida.

    XARTEMISXR is an oral medication indicated for the management of acute pain severe enough to require opioid treatment in patients for whom alternative treatment options (e.g., non-opioid analgesics) are ineffective, not tolerated or would otherwise be inadequate. It is the first and only oxycodone HCI/acetaminophen combination for acute pain with immediate- and extended-release analgesia, providing fast-acting and long-lasting pain relief with 12-hour dosing for patients. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for the treatment of the pain of osteoarthritis of the knee(s).

    The data to be presented on XARTEMIS XR evaluates pharmacokinetics in different populations, as well as pooled safety data from Phase III trials. The first presentation of pivotal efficacy and safety results for PENNSAID 2% in the treatment of pain for osteoarthritis of the knee will also be presented, as well as an assessment of pharmacokinetics and tolerability compared with the 1.5% PENNSAID formulation.

    “Mallinckrodt is committed to providing a diverse range of products for patients with different types of pain,” said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt(MNK). “The data we are sharing at APS will help further educate physicians about the characteristics and use of our two most recently launched products, XARTEMIS XR and PENNSAID 2%.”

    The abstracts to be presented are:

    XARTEMIS XR data

    Single-Dose Population Pharmacokinetics of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) Under Fed and Fasted Conditions (Abstract 426)
    Population Pharmacokinetics of Oxycodone Following a Single Oral Dose of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) (Abstract 436)
    Population Pharmacokinetics of Acetaminophen Following a Single Oral Dose of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) (Abstract 434)
    Population Pharmacokinetics of Oxycodone Following Multiple Oral Doses of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) (Abstract 433)
    Variability in the Pharmacokinetics of Acetaminophen Following Multiple Dose Administration of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) Is Affected by Covariates (Abstract 416)
    Safety and Tolerability of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) in Phase III Clinical Trials (Abstract 424)
    PENNSAID 2% data

    A Comparison of the Pharmacokinetics and Tolerability of Diclofenac Sodium 2% and 1.5% Topical Solutions (Abstract 485)
    An Assessment of the Efficacy and Tolerability of Diclofenac Sodium 2% Topical Solution for Treating Osteoarthritis of the Knee (Abstract 484)
    PENNSAID 2% Pivotal Trial Results

    The pivotal data presented at APS supported the January 17, 2014U.S. Food and Drug Administration approval of PENNSAID 2%. This double-blind, randomized, controlled, parallel-group study assessed the efficacy and tolerability of twice-daily PENNSAID 2% topical solution vs. vehicle in 259 patients with primary osteoarthritis of the knee. After four weeks, PENNSAID 2% produced significantly greater improvements in pain reduction – as measured by reductions in WOMAC® (Western Ontario and McMaster University Osteoarthritis Index) pain scores (-4.4 [0.4]) vs. (-3.4 [0.4]; P=0.040) – associated with osteoarthritis of the knee compared to vehicle control.

    Similar results were observed for secondary endpoints including WOMAC physical function (-13.9 [1.2] vs. -10.7 [1.3]; P=0.061) and stiffness (-1.7 [0.2] vs. -1.3 [0.2]; P=0.097) as well as patient global assessment of osteoarthritis status (-1.1 [0.1] vs. -0.8 [0.1]; P=0.085). None of these measures were statistically significant however. PENNSAID 2% was generally well tolerated. The vehicle control group experienced slightly more adverse events than active treatment (38.8% vs. 31.5%), which primarily involved application site reactions.

    About WOMAC ®

    WOMAC® is a registered trademark of Nicholas Bellamy. WOMAC is a proprietary health status questionnaire. For further information visit the WOMAC website at www.WOMAC.com.

    XARTEMIS ™ XR (oxycodone HCl and acetaminophen) Extended-Release Tablets, for oral use, CII

    INDICATIONS AND USAGE

    XARTEMIS™ XR (oxycodone HCl and acetaminophen) Extended-Release Tablets (CII) is indicated for the management of acute pain severe enough to require opioid treatment and for which alternative treatment options are inadequate. Because of the risks of addiction, abuse, misuse, overdose, and death with opioids, even at recommended doses, reserve XARTEMIS XR for use in patients for whom alternative treatment options (e.g., non-opioid analgesics) are ineffective, not tolerated or would be otherwise inadequate.

    IMPORTANT RISK INFORMATION

    WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and HEPATOTOXICITY

    Addiction, Abuse, and Misuse

    XARTEMIS XR exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing XARTEMIS XR, and monitor all patients regularly for the development of these behaviors or conditions.

    Life-threatening Respiratory Depression

    Serious, life-threatening, or fatal respiratory depression may occur with use of XARTEMIS XR. Monitor for respiratory depression, especially during initiation of XARTEMIS XR or following a dose increase. Instruct patients to swallow XARTEMIS XR tablets whole; crushing, chewing, or dissolving XARTEMIS XR can cause rapid release and absorption of a potentially fatal dose of oxycodone.

    Accidental Exposure

    Accidental ingestion of XARTEMIS XR, especially in children, can result in a fatal overdose of oxycodone.

    Neonatal Opioid Withdrawal Syndrome

    Prolonged use of XARTEMIS XR during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

    Hepatotoxicity

    XARTEMIS XR contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the maximum daily limit, and often involve more than one acetaminophen-containing product.

    CONTRAINDICATIONS

    XARTEMIS XR is contraindicated in patients with:
    known hypersensitivity to oxycodone, acetaminophen, or any other component of this product.
    significant respiratory depression.
    acute or severe bronchial asthma or hypercarbia.
    known or suspected paralytic ileus.
    WARNINGS AND PRECAUTIONS

    XARTEMIS XR contains oxycodone, a Schedule II controlled substance. As an opioid, XARTEMIS XR exposes users to the risks of addiction, abuse, and misuse. Abuse or misuse of XARTEMIS XR by crushing, chewing, snorting, or injecting the dissolved product will result in the uncontrolled delivery of the oxycodone and can result in overdose and death. With intravenous abuse, the inactive ingredients in XARTEMIS XR can result in death, local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and valvular heart injury. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.
    Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of XARTEMIS XR, the risk is greatest during the initiation of therapy or following a dose increase. Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients. In patients with significant chronic obstructive pulmonary disease or cor pulmonale, and patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, XARTEMIS XR may decrease respiratory drive to the point of apnea.
    Hypotension, profound sedation, coma, respiratory depression, and death may result if XARTEMIS XR is used concomitantly with alcohol or other central nervous system (CNS) depressants.
    The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.
    Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal.
    The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure.
    Oxycodone may cause severe hypotension particularly in individuals whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs which compromise vasomotor tone such as phenothiazines.
    Due to the potential for acetaminophen hepatotoxicity at doses higher than 4,000 milligrams/day, XARTEMIS XR should not be used concomitantly with other acetaminophen- containing products.
    Hypersensitivity and anaphylaxis associated with use of acetaminophen have been reported. Clinical signs included swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting.
    Due to characteristics of the formulation that cause the tablets to swell and become sticky when wet, consider use of an alternative analgesic in patients who have difficulty swallowing and patients at risk for underlying GI disorders resulting in a small gastrointestinal lumen. Instruct patients not to pre-soak, lick or otherwise wet XARTEMIS XR tablets prior to placing in the mouth, and to take one tablet at a time with enough water to ensure complete swallowing immediately after placing in mouth.
    Opioids diminish propulsive peristaltic waves in the gastrointestinal tract and decrease bowel motility. Oxycodone may cause spasm of the Sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis.
    Since the CYP3A4 isoenzyme plays a major role in the metabolism of XARTEMIS XR, drugs that alter CYP3A4 activity may cause changes in clearance of oxycodone which could lead to changes in oxycodone plasma concentrations.
    XARTEMIS XR may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this drug should be cautioned accordingly.
    ADVERSE REACTIONS

    Serious adverse events may include respiratory depression and hepatotoxicity.
    Common adverse events include nausea, dizziness, headache, vomiting, constipation and somnolence.
    USE IN SPECIFIC POPULATIONS

    Pregnancy: Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. Prolonged use of XARTEMIS XR during pregnancy can result in withdrawal signs in the neonate, which can be life threatening.
    Breast feeding: Oxycodone is present in human milk and may result in accumulation and toxicities such as sedation and respiratory depression in some infants. Acetaminophen is present in human milk in small quantities.
    Pediatrics: Safety and effectiveness in pediatric patients under the age of 18 years have not been established.
    See Full Prescribing Information for additional Important Risk Information including boxed warning.

    About XARTEMIS XR

    XARTEMIS XR is an extended-release oral formulation of oxycodone hydrochloride and acetaminophen with immediate-release and extended-release components. It is not interchangeable with other oxycodone/acetaminophen products because of differing pharmacokinetic profiles that affect the frequency of administration. XARTEMIS XR is a schedule II controlled substance.

    PENNSAID ® (diclofenac sodium topical solution) 2% w/w

    INDICATIONS AND USAGE

    PENNSAID® (diclofenac sodium topical solution) 2% w/w is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain of osteoarthritis of the knee(s).

    IMPORTANT RISK INFORMATION

    WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK

    Cardiovascular Risk

    Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
    PENNSAID is contraindicated in the perioperative setting of coronary artery bypass graft (CABG) surgery.
    Gastrointestinal Risk

    NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.
    CONTRAINDICATIONS

    PENNSAID is also contraindicated in patients:
    with a known hypersensitivity to diclofenac sodium or any other component of PENNSAID.
    who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal anaphylactic-like reactions to NSAIDs have been reported in such patients.
    WARNINGS AND PRECAUTIONS

    Elevation of one or more liver tests may occur during therapy with NSAIDs. PENNSAID should be discontinued immediately if abnormal liver tests persist or worsen.
    Use with caution in patients with fluid retention or heart failure. Hypertension can occur with NSAID treatment. Monitor blood pressure closely with PENNSAID treatment.
    Long-term administration of NSAIDs can result in renal papillary necrosis and other renal injury. Use PENNSAID with caution in patients at greatest risk of this reaction, including the elderly, those with impaired renal function, heart failure, liver dysfunction, and those taking diuretics and ACE-inhibitors.
    Anaphylactoid reactions may occur in patients without prior exposure to PENNSAID. NSAIDs can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal.
    Wash and dry hands before and after use. Avoid contact of PENNSAID with the eyes and mucous membranes.
    PENNSAID was not evaluated under the conditions of heat application, occlusive dressings overlay, or exercise; therefore, concurrent use of PENNSAID under these conditions is not recommended.
    Do not:
    apply PENNSAID to open wounds.
    shower for at least 30 minutes after applying PENNSAID.
    wear clothing over the PENNSAID treated knee until the treated knee is dry.
    Protect treated knee(s) from natural or artificial sunlight. Topicals, such as sunscreen and bug repellent, may be applied after PENNSAID treated knee(s) are completely dry.
    Concurrent use with oral NSAIDs should be avoided unless benefit outweighs risk and periodic laboratory evaluations are conducted.
    ADVERSE REACTIONS

    The most common adverse events in a phase 2 clinical trial of PENNSAID 2% were application site reactions, such as dryness (22%), exfoliation (7%), erythema (4%), pruritus (2%), pain (2%), induration (2%), rash (2%), and scabbing ( 1% of patients receiving PENNSAID 2% included urinary tract infection (3%), contusion (2%), sinus congestion (2%), and nausea (2%).
    The most common treatment-related adverse events in patients receiving PENNSAID 1.5% were application site skin reactions including dry skin (32%), contact dermatitis characterized by skin erythema and induration (9%), contact dermatitis with vesicles (2%) and pruritus (4%). In a long term safety study, contact dermatitis occurred in 13% and contact dermatitis with vesicles in 10% of patients, generally within the first 6 months of exposure, leading to a withdrawal rate for an application site event of 14%. Other common adverse events greater than placebo include: dyspepsia (9%), abdominal pain (6%), flatulence (4%), diarrhea (4%) and nausea (4%).
    USE IN SPECIFIC POPULATIONS

    PENNSAID should not be used in pregnant or lactating women and is not approved for use in pediatric patients.
    See Full Prescribing Information for additional Important Risk Information including boxed warning.

    About PENNSAID 2%

    PENNSAID is a registered trademark of Nuvo Research Inc. PENNSAID 2% is a follow-on product to original PENNSAID 1.5%. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) containing 2% diclofenac sodium compared to 1.5% for original PENNSAID 1.5%. It is more viscous than original PENNSAID 1.5%, is supplied in a metered dose pump bottle and has been approved for twice daily dosing compared to four times a day for original PENNSAID 1.5%.

    About Mallinckrodt(MNK)

    Mallinckrodt (MNK) is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt(MNK) has approximately 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company’s fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt(MNK), visit www.mallinckrodt.com.

    FORWARD-LOOKING STATEMENTS

    Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future financial condition and operating results, economic, business, competitive and/or regulatory factors affecting our business. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, our ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration, our ability to obtain and/or timely transport molybdenum-99 to our technetium-99m generator production facilities, customer concentration, cost-containment efforts of customers, purchasing groups, third-party payors and governmental organizations, our ability to successfully develop or commercialize new products, our ability to protect intellectual property rights, competition, our ability to integrate acquisitions of technology, products and businesses, product liability losses and other litigation liability, the reimbursement practices of a small number of large public or private issuers, complex reporting and payment obligation under healthcare rebate programs, changes in laws and regulations, conducting business internationally, foreign exchange rates, material health, safety and environmental liabilities, litigation and violations, information technology infrastructure and restructuring activities. These and other factors are identified and described in more detail in the “Risk Factors” section of Mallinckrodt’s Annual Report on Form 10-K for the fiscal year ended September 27, 2013 and in subsequent filings. We disclaim any obligation to update these forward-looking statements other than as required by law.

    Source: Mallinckrodt(MNK)

    Copyright Business Wire 2014

    Sentiment: Strong Buy

  • Reply to

    OT RTRX Down To $11.44

    by southofwaverly May 7, 2014 3:10 PM
    sam_0534 sam_0534 May 7, 2014 3:21 PM Flag

    more to come with the fraudster..

    Sentiment: Strong Sell

  • Thank you for voting. Your instructions have been received and recorded for:

    MALLINCKRODT PLC
    Meeting to be held on Thursday, August 14, 2014
    For Shareholders of record as of Wednesday, July 9, 2014
    CUSIP: G5785G107

    Sentiment: Strong Buy

  • sam_0534 by sam_0534 Apr 25, 2014 9:19 AM Flag

    UPGRADE: Mallinckrodt plc (MNK) upgraded by CRT Capital from Sell to Fair Value. 04/25 06:16 AM

    Get more news on:SYMBOLS: MNKNEWS TYPE: Analyst Ratings, Ratings: Upgrades and Downgrades, Ratings: UpgradesSECTORS:

  • April 24, 2014
    Questcor to Report First Quarter Financial Results on April 28, 2014
    ANAHEIM, Calif., April 24, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release first quarter 2014 financial results on Monday, April 28, 2014 after the close of the U.S. financial markets. In light of Questcor's pending merger with Mallinckrodt plc, the Company will not be hosting a conference call to discuss its financial results. Further details will be available in a Form 10-Q filing to be filed with the Securities and Exchange Commission after the earnings release.

    About Questcor

    Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. For more information about Questcor, please visit www.questcor.com

    SOURCE Questcor Pharmaceuticals, Inc.

    News Provided by Acquire Media

    Sentiment: Strong Buy

  • the stocastics in the oversold area has given a buy signal.. the wirh fast moving above the slow...http://finance.yahoo.com/q/ta?t=1y&l=on&z=l&q=b&p=m50%2Cm100%2Cm200&a=m26-12-9%2Cr14%2Css%2Cv&c=&s=mnk&ql=1

    Sentiment: Strong Buy

  • QCOR is set to close 3rd quarter.. no hurdles and on takget. spent some time on QCOR and favorable..

    Sentiment: Strong Buy

  • Reply to

    MNK UP $2.20

    by caffeinsomniac Apr 28, 2014 3:11 PM
    sam_0534 sam_0534 Apr 28, 2014 4:49 PM Flag

    there is more weird action BX came out with great earning and a big dividend and it has been selling off. I am not selling..

  • Reply to

    Buy in may - the shorts will pray

    by nyjohnnygray May 7, 2014 11:45 PM
    sam_0534 sam_0534 May 8, 2014 10:27 AM Flag

    the shorts will PAY :(

  • SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. )*

    QUESTCOR PHARMACEUTICALS, INC.

    (Name of Issuer)

    Common Stock, no par value

    (Title of Class of Securities)

    74835Y101

    (CUSIP Number)

    April 24, 2014

    (Date of Event Which Requires Filing of This Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

    (Page 1 of 12 Pages)



    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





    CUSIP No. 74835Y101 13G Page 2 of 12 Pages



    1 NAME OF REPORTING PERSON

    Adage Capital Partners, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH: 5 SOLE VOTING POWER

    0

    6 SHARED VOTING POWER

    3,859,157

    7 SOLE DISPOSITIVE POWER

    0

    8 SHARED DISPOSITIVE POWER

    3,859,157

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,859,157

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.33%

    12 TYPE OF REPORTING PERSON

    PN







    CUSIP No. 74835Y101 13G Page 3 of 12 Pages





    1 NAME OF REPORTING PERSON

    Adage Capital Partners GP, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH: 5 SOLE VOTING POWER

    0

    6 SHARED VOTING POWER

    3,859,157

    7 SOLE DISPOSITIVE POWER

    0

    8 SHARED DISPOSITIVE POWER

    3,859,157

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,859,157

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.33%

    12 TYPE OF REPORTING PERSON

    OO









    CUSIP No. 74835Y101 13G Page 4 of 12 Pages





    1 NAME OF REPORTING PERSON

    Adage Capital Advisors, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH: 5 SOLE VOTING POWER

    0

    6 SHARED VOTING POWER

    3,859,157

    7 SOLE DISPOSITIVE POWER

    0

    8 SHARED DISPOSITIVE POWER

    3,859,157

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,859,157

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.33%

    12 TYPE OF REPORTING PERSON

    OO







    CUSIP No. 74835Y101 13G Page 5 of 12 Pages





    1 NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH: 5 SOLE VOTING POWER

    0

    6 SHARED VOTING POWER

    3,859,157

    7 SOLE DISPOSITIVE POWER

    0

    8 SHARED DISPOSITIVE POWER

    3,859,157

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,859,157

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.33%

    12 TYPE OF REPORTING PERSON

    IN







    CUSIP No. 74835Y101 13G Page 6 of 12 Pages





    1 NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH: 5 SOLE VOTING POWER

    0

    6 SHARED VOTING POWER

    3,859,157

    7 SOLE DISPOSITIVE POWER

    0

    8 SHARED DISPOSITIVE POWER

    3,859,157

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,859,157

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.33%

    12 TYPE OF REPORTING PERSON

    IN







    CUSIP No. 74835Y101 13G Page 7 of 12 Pages





    Item 1(a). NAME OF ISSUER
    The name of the issuer is QUESTCOR PHARMACEUTICALS, INC. (the “Company”).



    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
    The Company’s principal executive offices are located at 1300 North Kellogg Drive, Suite D, Anaheim, California 94105.



    Item 2(a). NAME OF PERSON FILING
    This statement is filed by:

    (i) Adage Capital Partners, L.P., a Delaware limited partnership ("ACP") with respect to the shares of Common Stock directly owned by it;

    (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), as general partner of ACP with respect to the shares of Common Stock directly owned by ACP;

    (iii) Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), as managing member of ACPGP, general partner of ACP, with respect to the shares of Common Stock directly owned by ACP;

    (iv) Robert Atchinson ("Mr. Atchinson"), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP; and

    (v) Phillip Gross ("Mr. Gross"), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP.

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.



    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
    The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd floor, Boston, Massachusetts 02116.



    Item 2(c). CITIZENSHIP
    ACP is a limited partnership organized under the laws of the State of Delaware. ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.






    CUSIP No. 74835Y101 13G Page 8 of 12 Pages



    Item 2(d). TITLE OF CLASS OF SECURITIES
    Common Stock, no par value (the "Common Stock").



    Item 2(e). CUSIP NUMBER
    74835Y101



    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:



    (a) ¨ Broker or dealer registered under Section 15 of the Act;
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
    (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
    (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).



    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: Not applicable.








    CUSIP No. 74835Y101 13G Page 9 of 12 Pages



    Item 4. OWNERSHIP



    A. Adage Capital Partners, L.P., Adage Capital Partners GP, L.L.C. and Adage Capital Advisors, L.L.C.
    (a) Amount beneficially owned: 3,859,157
    (b) Percent of class: 6.33%. The percentages used herein and in the rest of Item 4 are calculated based upon 60,977,015 shares of Common Stock outstanding as of March 31, 2014 as reported in the Company’s Form 10-Q dated April 29, 2014.
    (c) (i) Sole power to vote or direct the vote: 0
    (ii) Shared power to vote or direct the vote: 3,859,157
    (iii) Sole power to dispose or direct the disposition: 0
    (iv) Shared power to dispose or direct the disposition of: 3,859,157



    ACP has the power to dispose of and the power to vote the shares of Common Stock beneficially owned by it, which power may be exercised by its general partner, ACPGP. ACA, as managing member of ACPGP, directs ACPGP's operations. Neither ACPGP nor ACA directly own any shares of Common Stock. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934 (the "Act"), ACPGP and ACA may be deemed to beneficially own the shares owned by ACP.



    B. Robert Atchinson and Phillip Gross
    (a) Amount beneficially owned: 3,859,157
    (b) Percent of class: 6.33%
    (c) (i) Sole power to vote or direct the vote: 0
    (ii) Shared power to vote or direct the vote: 3,859,157
    (iii) Sole power to dispose or direct the disposition: 0
    (iv) Shared power to dispose or direct the disposition: 3,859,157



    Messrs. Atchinson and Gross, as managing members of ACA, have shared power to vote the Common Stock beneficially owned by ACP. Neither Mr. Atchinson nor Mr. Gross directly own any shares of Common Stock. By reason of the provisions of Rule 13d-3 of the Act, each may be deemed to beneficially own the shares beneficially owned by ACP.



    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
    Not applicable.



    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
    Not applicable.




    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
    Not applicable.





    CUSIP No. 74835Y101 13G Page 10 of 12 Pages





    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
    Not applicable.



    Item 9. NOTICE OF DISSOLUTION OF GROUP
    Not applicable.





    Item 10. CERTIFICATION



    Each of the Reporting Persons hereby makes the following certification:

    By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.





    CUSIP No. 74835Y101 13G Page 11 of 12 Pages



    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: May 2, 2014




    ADAGE CAPITAL PARTNERS, L.P.
    By: Adage Capital Partners GP, L.L.C.,
    its general partner

    By: Adage Capital Advisors, L.L.C.,
    its managing member

    /s/ Robert Atchinson
    Name: Robert Atchinson
    Title: Managing Member

    ADAGE CAPITAL PARTNERS GP, L.L.C.
    By: Adage Capital Advisors, L.L.C.,
    its managing member

    /s/ Robert Atchinson
    Name: Robert Atchinson
    Title: Managing Member

    ADAGE CAPITAL ADVISORS, L.L.C.

    /s/ Robert Atchinson
    Name: Robert Atchinson
    Title: Managing Member


    /s/ Robert Atchinson
    ROBERT ATCHINSON, individually


    /s/ Phillip Gross
    PHILLIP GROSS, individually





    CUSIP No. 74835Y101 13G Page 12 of 12 Pages

    EXHIBIT 1

    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.



    DATE: May 2, 2014



    ADAGE CAPITAL PARTNERS, L.P.
    By: Adage Capital Partners GP, L.L.C.,
    its general partner

    By: Adage Capital Advisors, L.L.C.,
    its managing member

    /s/ Robert Atchinson
    Name: Robert Atchinson
    Title: Managing Member

    ADAGE CAPITAL PARTNERS GP, L.L.C.
    By: Adage Capital Advisors, L.L.C.,
    its managing member

    /s/ Robert Atchinson
    Name: Robert Atchinson
    Title: Managing Member

    ADAGE CAPITAL ADVISORS, L.L.C.

    /s/ Robert Atchinson
    Name: Robert Atchinson
    Title: Managing Member


    /s/ Robert Atchinson
    ROBERT ATCHINSON, individually


    /s/ Phillip Gross
    PHILLIP GROSS, individually

    Sentiment: Strong Buy

  • Reply to

    My opinion

    by teberb May 24, 2014 1:57 PM
    sam_0534 sam_0534 May 25, 2014 12:20 PM Flag

    I was impressed that IPCI came back from that low of 3.50 Friday...on a big block sell at the opening time...still a very volatile and thinly traded stock....but as you see onthis chart link, the stocastics are very oversold and a buy here is low risk IMHO...http://finance.yahoo.com/q/ta?t=1y&l=on&z=l&q=b&p=m50%2Cm100%2Cm200%2Cv&a=m26-12-9%2Cr14%2Css&c=&s=ipci&ql=1

    Sentiment: Strong Buy

  • Hillshire shareholders must vote on the Pinnacle deal, which is still governed by a formal merger agreement. But with Hillshire shares up 40% this week based on its status as prey, it’s hard to see it going through. As noted here Monday, Pinnacle – controlled by buyout shop Blackstone Group – will likely end up “in play” down the road, even if it’s cut loose by Hillshire.

  • View photo
    Adam Jeffery | CNBC

    The U.S. should make it harder for companies to reap tax benefits from merging with foreign corporations, former Treasury Secretary Tim Geithner said in a wide-ranging interview on CNBC that aired Monday.

    The recent debate over these tax-driven deals kicked into high gear with Pfizer (PFE)'s $106 billion offer to buy its British rival AstraZeneca (London Stock Exchange: AZN-GB). If completed, the American drug company could save billions of dollars by relocating to the U.K., where business taxes are lower.

    Geithner said in the interview on " Squawk Box " the foreign merger situation showed the need for the Obama administration's 2012 corporate tax reform plan, which failed to win support. "It was to address, partly, this risk [and] to try to create a system where there's better incentives for investment."

    Under the plan unveiled in February 2012, the White House proposed eliminating tax loopholes and lowering the corporate tax rate from 35 percent to 28 percent. It had also sought to reduce provisions that allow companies to shift income and investment outside the U.S. while giving tax credits to American companies to bring operations back.

    "In the absence of comprehensive reform, you can still

  • sam_0534 by sam_0534 Jul 18, 2014 9:43 AM Flag

    NEW YORK (TheStreet) -- JMP Securities increased its price target on The Blackstone Group (BX_) to $44, increased its estimates and set a "buy" rating, as the company is seeing higher asset growth.

    Sentiment: Strong Buy

  • so they have a valid platform and would expect others to follow...just need to be patient...

    Sentiment: Strong Buy

  • sam_0534 sam_0534 Jul 2, 2014 9:58 AM Flag

    you are wasting others time here with your posts...I will have to put you on IGNORE and others should too if you keep up your foolish posts... ciao

    Sentiment: Buy

  • sam_0534 by sam_0534 Apr 30, 2014 9:16 AM Flag

    ActiveTraderPro.com BannerPrint Print
    A A A
    All Content and Data provided by Third-Parties — Terms of Use
    Mallinckrodt Pharmaceuticals to Present New Clinical Data at American Pain Society Annual Scientific MeetingXARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) and PENNSAID® 2% (diclofenac sodium topical solution 2% w/w) Studies Offer Additional Product Information
    BUSINESS WIRE 6:00 AM ET 4/30/2014
    Symbol Last Price Change
    MNK 68.6down 0 (0%)
    QUOTES AS OF 04:04:06 PM ET 04/29/2014
    TAMPA, Fla.--(BUSINESS WIRE)-- Mallinckrodt(MNK) will present new data for two of its recently approved pain medications – XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) and PENNSAID® 2% (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) – during the 33rd Annual Scientific Meeting of the American Pain Society (APS) to be held April 30 - May 3, 2014 in Tampa, Florida.

    XARTEMISXR is an oral medication indicated for the management of acute pain severe enough to require opioid treatment in patients for whom alternative treatment options (e.g., non-opioid analgesics) are ineffective, not tolerated or would otherwise be inadequate. It is the first and only oxycodone HCI/acetaminophen combination for acute pain with immediate- and extended-release analgesia, providing fast-acting and long-lasting pain relief with 12-hour dosing for patients. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for the treatment of the pain of osteoarthritis of the knee(s).

    The data to be presented on XARTEMIS XR evaluates pharmacokinetics in different populations, as well as pooled safety data from Phase III trials. The first presentation of pivotal efficacy and safety results for PENNSAID 2% in the treatment of pain for osteoarthritis of the knee will also be presented, as well as an assessment of pharmacokinetics and tolerability compared with the 1.5% PENNSAID formulation.

    “Mallinckrodt is committed to providing a diverse range of products for patients with different types of pain,” said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt(MNK). “The data we are sharing at APS will help further educate physicians about the characteristics and use of our two most recently launched products, XARTEMIS XR and PENNSAID 2%.”

    The abstracts to be presented are:

    XARTEMIS XR data

    Single-Dose Population Pharmacokinetics of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) Under Fed and Fasted Conditions (Abstract 426)
    Population Pharmacokinetics of Oxycodone Following a Single Oral Dose of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) (Abstract 436)
    Population Pharmacokinetics of Acetaminophen Following a Single Oral Dose of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) (Abstract 434)
    Population Pharmacokinetics of Oxycodone Following Multiple Oral Doses of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) (Abstract 433)
    Variability in the Pharmacokinetics of Acetaminophen Following Multiple Dose Administration of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) Is Affected by Covariates (Abstract 416)
    Safety and Tolerability of MNK-795 (Oxycodone and Acetaminophen Extended-Release Tablets) in Phase III Clinical Trials (Abstract 424)
    PENNSAID 2% data

    A Comparison of the Pharmacokinetics and Tolerability of Diclofenac Sodium 2% and 1.5% Topical Solutions (Abstract 485)
    An Assessment of the Efficacy and Tolerability of Diclofenac Sodium 2% Topical Solution for Treating Osteoarthritis of the Knee (Abstract 484)
    PENNSAID 2% Pivotal Trial Results

    The pivotal data presented at APS supported the January 17, 2014U.S. Food and Drug Administration approval of PENNSAID 2%. This double-blind, randomized, controlled, parallel-group study assessed the efficacy and tolerability of twice-daily PENNSAID 2% topical solution vs. vehicle in 259 patients with primary osteoarthritis of the knee. After four weeks, PENNSAID 2% produced significantly greater improvements in pain reduction – as measured by reductions in WOMAC® (Western Ontario and McMaster University Osteoarthritis Index) pain scores (-4.4 [0.4]) vs. (-3.4 [0.4]; P=0.040) – associated with osteoarthritis of the knee compared to vehicle control.

    Similar results were observed for secondary endpoints including WOMAC physical function (-13.9 [1.2] vs. -10.7 [1.3]; P=0.061) and stiffness (-1.7 [0.2] vs. -1.3 [0.2]; P=0.097) as well as patient global assessment of osteoarthritis status (-1.1 [0.1] vs. -0.8 [0.1]; P=0.085). None of these measures were statistically significant however. PENNSAID 2% was generally well tolerated. The vehicle control group experienced slightly more adverse events than active treatment (38.8% vs. 31.5%), which primarily involved application site reactions.

    About WOMAC ®

    WOMAC® is a registered trademark of Nicholas Bellamy. WOMAC is a proprietary health status questionnaire. For further information visit the WOMAC website at www.WOMAC.com.

    XARTEMIS ™ XR (oxycodone HCl and acetaminophen) Extended-Release Tablets, for oral use, CII

    INDICATIONS AND USAGE

    XARTEMIS™ XR (oxycodone HCl and acetaminophen) Extended-Release Tablets (CII) is indicated for the management of acute pain severe enough to require opioid treatment and for which alternative treatment options are inadequate. Because of the risks of addiction, abuse, misuse, overdose, and death with opioids, even at recommended doses, reserve XARTEMIS XR for use in patients for whom alternative treatment options (e.g., non-opioid analgesics) are ineffective, not tolerated or would be otherwise inadequate.

    IMPORTANT RISK INFORMATION

    WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and HEPATOTOXICITY

    Addiction, Abuse, and Misuse

    XARTEMIS XR exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing XARTEMIS XR, and monitor all patients regularly for the development of these behaviors or conditions.

    Life-threatening Respiratory Depression

    Serious, life-threatening, or fatal respiratory depression may occur with use of XARTEMIS XR. Monitor for respiratory depression, especially during initiation of XARTEMIS XR or following a dose increase. Instruct patients to swallow XARTEMIS XR tablets whole; crushing, chewing, or dissolving XARTEMIS XR can cause rapid release and absorption of a potentially fatal dose of oxycodone.

    Accidental Exposure

    Accidental ingestion of XARTEMIS XR, especially in children, can result in a fatal overdose of oxycodone.

    Neonatal Opioid Withdrawal Syndrome

    Prolonged use of XARTEMIS XR during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

    Hepatotoxicity

    XARTEMIS XR contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the maximum daily limit, and often involve more than one acetaminophen-containing product.

    CONTRAINDICATIONS

    XARTEMIS XR is contraindicated in patients with:
    known hypersensitivity to oxycodone, acetaminophen, or any other component of this product.
    significant respiratory depression.
    acute or severe bronchial asthma or hypercarbia.
    known or suspected paralytic ileus.
    WARNINGS AND PRECAUTIONS

    XARTEMIS XR contains oxycodone, a Schedule II controlled substance. As an opioid, XARTEMIS XR exposes users to the risks of addiction, abuse, and misuse. Abuse or misuse of XARTEMIS XR by crushing, chewing, snorting, or injecting the dissolved product will result in the uncontrolled delivery of the oxycodone and can result in overdose and death. With intravenous abuse, the inactive ingredients in XARTEMIS XR can result in death, local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and valvular heart injury. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.
    Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of XARTEMIS XR, the risk is greatest during the initiation of therapy or following a dose increase. Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients. In patients with significant chronic obstructive pulmonary disease or cor pulmonale, and patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, XARTEMIS XR may decrease respiratory drive to the point of apnea.
    Hypotension, profound sedation, coma, respiratory depression, and death may result if XARTEMIS XR is used concomitantly with alcohol or other central nervous system (CNS) depressants.
    The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.
    Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal.
    The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure.
    Oxycodone may cause severe hypotension particularly in individuals whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs which compromise vasomotor tone such as phenothiazines.
    Due to the potential for acetaminophen hepatotoxicity at doses higher than 4,000 milligrams/day, XARTEMIS XR should not be used concomitantly with other acetaminophen- containing products.
    Hypersensitivity and anaphylaxis associated with use of acetaminophen have been reported. Clinical signs included swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting.
    Due to characteristics of the formulation that cause the tablets to swell and become sticky when wet, consider use of an alternative analgesic in patients who have difficulty swallowing and patients at risk for underlying GI disorders resulting in a small gastrointestinal lumen. Instruct patients not to pre-soak, lick or otherwise wet XARTEMIS XR tablets prior to placing in the mouth, and to take one tablet at a time with enough water to ensure complete swallowing immediately after placing in mouth.
    Opioids diminish propulsive peristaltic waves in the gastrointestinal tract and decrease bowel motility. Oxycodone may cause spasm of the Sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis.
    Since the CYP3A4 isoenzyme plays a major role in the metabolism of XARTEMIS XR, drugs that alter CYP3A4 activity may cause changes in clearance of oxycodone which could lead to changes in oxycodone plasma concentrations.
    XARTEMIS XR may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this drug should be cautioned accordingly.
    ADVERSE REACTIONS

    Serious adverse events may include respiratory depression and hepatotoxicity.
    Common adverse events include nausea, dizziness, headache, vomiting, constipation and somnolence.
    USE IN SPECIFIC POPULATIONS

    Pregnancy: Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. Prolonged use of XARTEMIS XR during pregnancy can result in withdrawal signs in the neonate, which can be life threatening.
    Breast feeding: Oxycodone is present in human milk and may result in accumulation and toxicities such as sedation and respiratory depression in some infants. Acetaminophen is present in human milk in small quantities.
    Pediatrics: Safety and effectiveness in pediatric patients under the age of 18 years have not been established.
    See Full Prescribing Information for additional Important Risk Information including boxed warning.

    About XARTEMIS XR

    XARTEMIS XR is an extended-release oral formulation of oxycodone hydrochloride and acetaminophen with immediate-release and extended-release components. It is not interchangeable with other oxycodone/acetaminophen products because of differing pharmacokinetic profiles that affect the frequency of administration. XARTEMIS XR is a schedule II controlled substance.

    PENNSAID ® (diclofenac sodium topical solution) 2% w/w

    INDICATIONS AND USAGE

    PENNSAID® (diclofenac sodium topical solution) 2% w/w is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain of osteoarthritis of the knee(s).

    IMPORTANT RISK INFORMATION

    WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK

    Cardiovascular Risk

    Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
    PENNSAID is contraindicated in the perioperative setting of coronary artery bypass graft (CABG) surgery.
    Gastrointestinal Risk

    NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.
    CONTRAINDICATIONS

    PENNSAID is also contraindicated in patients:
    with a known hypersensitivity to diclofenac sodium or any other component of PENNSAID.
    who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal anaphylactic-like reactions to NSAIDs have been reported in such patients.
    WARNINGS AND PRECAUTIONS

    Elevation of one or more liver tests may occur during therapy with NSAIDs. PENNSAID should be discontinued immediately if abnormal liver tests persist or worsen.
    Use with caution in patients with fluid retention or heart failure. Hypertension can occur with NSAID treatment. Monitor blood pressure closely with PENNSAID treatment.
    Long-term administration of NSAIDs can result in renal papillary necrosis and other renal injury. Use PENNSAID with caution in patients at greatest risk of this reaction, including the elderly, those with impaired renal function, heart failure, liver dysfunction, and those taking diuretics and ACE-inhibitors.
    Anaphylactoid reactions may occur in patients without prior exposure to PENNSAID. NSAIDs can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal.
    Wash and dry hands before and after use. Avoid contact of PENNSAID with the eyes and mucous membranes.
    PENNSAID was not evaluated under the conditions of heat application, occlusive dressings overlay, or exercise; therefore, concurrent use of PENNSAID under these conditions is not recommended.
    Do not:
    apply PENNSAID to open wounds.
    shower for at least 30 minutes after applying PENNSAID.
    wear clothing over the PENNSAID treated knee until the treated knee is dry.
    Protect treated knee(s) from natural or artificial sunlight. Topicals, such as sunscreen and bug repellent, may be applied after PENNSAID treated knee(s) are completely dry.
    Concurrent use with oral NSAIDs should be avoided unless benefit outweighs risk and periodic laboratory evaluations are conducted.
    ADVERSE REACTIONS

    The most common adverse events in a phase 2 clinical trial of PENNSAID 2% were application site reactions, such as dryness (22%), exfoliation (7%), erythema (4%), pruritus (2%), pain (2%), induration (2%), rash (2%), and scabbing ( 1% of patients receiving PENNSAID 2% included urinary tract infection (3%), contusion (2%), sinus congestion (2%), and nausea (2%).
    The most common treatment-related adverse events in patients receiving PENNSAID 1.5% were application site skin reactions including dry skin (32%), contact dermatitis characterized by skin erythema and induration (9%), contact dermatitis with vesicles (2%) and pruritus (4%). In a long term safety study, contact dermatitis occurred in 13% and contact dermatitis with vesicles in 10% of patients, generally within the first 6 months of exposure, leading to a withdrawal rate for an application site event of 14%. Other common adverse events greater than placebo include: dyspepsia (9%), abdominal pain (6%), flatulence (4%), diarrhea (4%) and nausea (4%).
    USE IN SPECIFIC POPULATIONS

    PENNSAID should not be used in pregnant or lactating women and is not approved for use in pediatric patients.
    See Full Prescribing Information for additional Important Risk Information including boxed warning.

    About PENNSAID 2%

    PENNSAID is a registered trademark of Nuvo Research Inc. PENNSAID 2% is a follow-on product to original PENNSAID 1.5%. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) containing 2% diclofenac sodium compared to 1.5% for original PENNSAID 1.5%. It is more viscous than original PENNSAID 1.5%, is supplied in a metered dose pump bottle and has been approved for twice daily dosing compared to four times a day for original PENNSAID 1.5%.

    About Mallinckrodt(MNK)

    Mallinckrodt (MNK) is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt(MNK) has approximately 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company’s fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt(MNK), visit www.mallinckrodt.com.

    FORWARD-LOOKING STATEMENTS

    Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future financial condition and operating results, economic, business, competitive and/or regulatory factors affecting our business. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, our ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration, our ability to obtain and/or timely transport molybdenum-99 to our technetium-99m generator production facilities, customer concentration, cost-containment efforts of customers, purchasing groups, third-party payors and governmental organizations, our ability to successfully develop or commercialize new products, our ability to protect intellectual property rights, competition, our ability to integrate acquisitions of technology, products and businesses, product liability losses and other litigation liability, the reimbursement practices of a small number of large public or private issuers, complex reporting and payment obligation under healthcare rebate programs, changes in laws and regulations, conducting business internationally, foreign exchange rates, material health, safety and environmental liabilities, litigation and violations, information technology infrastructure and restructuring activities. These and other factors are identified and described in more detail in the “Risk Factors” section of Mallinckrodt’s Annual Report on Form 10-K for the fiscal year ended September 27, 2013 and in subsequent filings. We disclaim any obligation to update these forward-looking statements other than as required by law.

    Source: Mallinckrodt(MNK)

    Copyright Business Wire 2014

    Sentiment: Strong Buy

  • sam_0534 sam_0534 May 21, 2014 12:44 PM Flag

    your opinion..I bought IPCI 09/20/2013 at 2.14 and 11/18/2013 at 1.90 due to OBV and stocastics..the charts work for me.:)... I am an BSME engineer and ex broker with E. F. Hutton and am 75..lots of experience...stocastics oversold.. good guy point.. i just bought another 1000 at 3.80.....

    Sentiment: Strong Buy

UNH
86.05+0.99(+1.16%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.